Cite
HARVARD Citation
Boquimpani, C. et al. (n.d.). Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Leukemia & lymphoma. 56 (6), pp. 1787-1792. [Online].